Background: Thyroid swelling is one of most common neck swelling encountered in clinical practice. Fine needle aspiration cytology (FNAC) is a reliable preoperative screening test to differentiate between benign and malignant lesions which helps in proper management of patient and avoiding unnecessary surgeries. Aims and Objectives: The present study was to evaluate various lesions of thyroid and classify them according to the Bethedsa system of reporting of thyroid cytopathology (TBSRTC) and to correlate FNAC with histopathology wherever possible. Materials and Methods: This study is a retrospective study of 225 cases of thyroid swelling conducted from May 2016 to April 2017 in the department of pathology, Government Royapettah Hospital, Kilpauk Medical College, Chennai. FNAC results were correlated with histopathological diagnosis wherever surgery was done. Results: This study includes 225 cases. Out of 225 cases of FNAC of thyroid lesions, 213 satisfactory cases were obtained. Maximum cases were benign lesion 233 cases (93.3%), malignant cases were 12 (5.3%) and 12 cases were unsatisfactory (5.3%) with diagnostic accuracy 99%, sensitivity 99% and specificity 100% Conclusion: FNAC is an effective tool for diagnosing various thyroid lesions as it is safe, cost effective and initial diagnostic modality that avoids unwanted surgeries.
Lipoblastoma is a peculiar variant of lipoma occurring almost exclusively during infancy and early childhood. It is found most commonly in the upper and lower extremities; less common sites are head and neck, trunk, mediastinum, and retroperitoneum. It has a greater predilection for boys and commonly presents as a slowly growing soft-tissue mass. We present here the case of a five- year old female child with a lipoblastoma presenting as a paravertebral mass in the right lower back which progressed rapidly in the previous six months causing diagnostic difficulty on fine needle aspiration cytology.
(2008) to overcome the problems of difficulty in classifying certain lymphomas having overlapping morphological, immunophenotypical and genetic features. To study the clinicopathological profile of BCLu-DLBCL/BL. Crosssectional study over 3 year period in the Haematology section of Department of Pathology in a large teaching hospital in Southern India from January 2011 to December 2013. All the cases reported as BCLu-DLBCL/BL were collected and the clinical, morphological and immunohistochemical parameters were analyzed. Descriptive statistics. There were seven cases, four males and three females, of age ranging from 20 to 70 years. Five cases had extranodal involvement. Four cases had Burkitt morphology with strong Bcl2 positivity and absent CD10 expression. One case had the morphology and immunophenotype that of typical BL, along with strong positivity to Bcl2 suggesting a double hit hypothesis. Two cases had morphology and immunophenotype of BL with low Ki 67. Three patients on follow up had adverse outcome. BCLu-DLBCL/BL, a provisional category in WHO 2008 is useful in classifying the cases not meeting the criteria for classical BL or DLBCL. Each of these cases was interesting with different sites of involvement, different morphological features and immunophenotype with most of the patients on follow up ending with a grave prognosis.
Bone marrow fat embolism usually occurs following multiple bone fractures, intraosseous surgical procedures, following vigorous cardiac resuscitation, ecclampsia, sickle cell anemia, malignancies, etc. We present a case of 70-year-old male who presented with fever, cough with expectoration, respiratory distress, altered sensorium, hypotension and thrombocytopenia, and diagnosed to have dengue shock syndrome and expired within 1 day of admission. Postmortem lung biopsy revealed bone marrow fat embolism.
Introduction:Neuroendocrine neoplasms are derived predominately from enterochromaffin or Kulchitsky's cells. The estimated prevalence of neuroendocrine tumors (NET) is 1 to 2 cases per 100,000 people, of which gastrointestinal tract (GIT) is the most common site. And being a rare tumor, it is less studied Aim of the Study: To study the clinicopathological profile of Neuroendocrine tumors of GIT. Materials and Methods: All specimens of neuroendocrine tumors received from the Department of Surgery and Department of digestive health diseases during the period from September 2008 to September 2012 were included. Clinical details were collected from the medical records in all cases. The tumors were classified based on WHO classification 2010 using morphological findings on H&E slides. Immunohistochemistry was done in 40 cases using Synaptophysin, Chromogranin and Neuron specific enolase. Results: There were 886 neoplasms diagnosed in GIT of which 53 (5.98%) were NET. The mean age of presentation was 50 years. The male: Female ratio observed is 2:1. The most common presenting symptoms were abdominal pain followed by loss of appetite and weight. Carcinoid syndrome was seen in 2/53 (3.8%) patients .The most common site involved was Stomach followed by duodenum and ileum. NET Grade 1 was seen in 22 cases, NET Grade 2 was seen in 9cases, NET Grade3 was seen 4 cases and mixed adenocarcinoma and neuroendocrine carcinoma (MANEC) was seen in 18 cases. Metastasis to liver was seen in 3 cases Most of the NET tumors expressed the IHC markers, 95% were positive for NSE, 87.5% were positive for Synaptophysin and 82.5% cases were positive for Chromogranin Conclusion: Neuroendocrine tumors (NETs) are uncommon malignancies of GIT. Stomach was the most common anatomical site. NET grade 1 was the most common histological subtype. IHC markers NSE, Synaptophysin and chromogranin can be used in diagnosis of NETs
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.